(Bloomberg) –Morgan Stanley and a group of investors are close to buying 30% of Turkish drugmaker Sanovel Ilac Sanayi ve Ticaret AS, according to people with knowledge of the matter.

London-based buyout firm Metric Capital Partners LLP is also part of the consortium that will pay almost $200 million for the stake in the producer of anti-inflammatory, anti-asthmatic and antibiotic medication, said the people, asking not to be identified because the information isn’t public.

Read: Novartis agrees to buy Medicines Co. in $6.8 billion deal

Representatives for Sanovel, Morgan Stanley and Metric Capital declined to comment. The deal is due to be signed next week, the people said.

The deal follows a failed attempt by Sanovel’s owners, Turkish businessmen Ahmet Toksoz and Zafer Toksoz, to sell a minority holding to Abraaj Group in 2018. The Dubai-based buyout firm, which once managed about $14 billion as the developing world’s most influential private equity investor, was forced into liquidation after mismanaging investor funds.